ABCB1 C3435T polymorphism is associated with susceptibility to major depression, but not with a clinical response to citalopram in a Turkish population

Pharmacological Reports

Volumn 66, Issue 2, 2014, Pages 235-238

  Ozbey, Gul ^a   Yucel, Berna ^b   Taycan, Serap E ^c   Kan, Derya ^d   Bodur, Nurdan E ^e   Arslan, Tayyibe ^f   Percin, Ferda ^d   Yuksel, Nevzat ^d   Guzey, Cuneyt ^g,h   Uluoglu, Canan ^d  

^a AKDENIZ UNIVERSITY   (Turkey)

^b MINISTRY OF HEALTH   (Turkey)

^c GAZIOSMANPASA UNIVERSITY   (Turkey)

^d GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^e Istanbul Erenkoy Training and Research Hospital For Psychiatry and Neurological Diseases   (Turkey)

^f Balikesir State Hospital   (Turkey)

^g TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^h NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

ABCB1; Citalopram; Depression; Polymorphism; Response

Indexed keywords

CITALOPRAM; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; ANTIDEPRESSANT AGENT; MULTIDRUG RESISTANCE PROTEIN;

ABCB1 GENE; ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENOTYPE; HAMILTON SCALE; HOMOZYGOSITY; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICATION COMPLIANCE; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; TURKEY (REPUBLIC); UNSPECIFIED SIDE EFFECT; DEPRESSIVE DISORDER, MAJOR; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEINS; POLYMORPHISM, GENETIC;

EID: 84899626280     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2013.09.004     Document Type: Article

References (37)

1. Bezchlibnyk-Butler K, Aleksic I, Kennedy SH. Citalopram-a review of pharmacological and clinical effects. J Psychiatry Neurosci 2000;25:241-54. (Pubitemid 30641001)
2. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (Pglycoprotein) gene from multidrug-resistant human cells. Cell 1986;47:381-9. (Pubitemid 17210152)
3. De Klerk OL, Willemsen AT, Roosink M, Bartels AL, Hendrikse NH, Bosker FJ, et al. Locally increased P-glycoprotein function in major depression: a PET study with [11C] verapamil as a probe for P-glycoprotein function in the blood-brain barrier. Int J Neuropsychopharmacol 2009;12:895-904.
4. De Kloet ER, Vreugdenhil E, Oitzl MS, Joë ls M. Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998;19:269-301. (Pubitemid 29117816)
5. Dericioglu N, Babaoglu MO, Yasar U, Bal IB, Bozkurt A, Saygi S. Multidrug resistance in patients undergoing resective epilepsy surgery is not associated with C3435T polymorphism in the ABCB1 (MDR1) gene Epilepsy Res. 2008 80 42-46.
6. Duverneuil C, de la Grandmaison GL, de Mazancourt P, Alvarez JC. A highperformance liquid chromatography method with photodiode-array UV detection for therapeutic drug monitoring of the nontricyclic antidepressant drugs. Ther Drug Monit 2003;25:565-73. (Pubitemid 37238890)
7. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53:649-59. (Pubitemid 39658481)
8. Fujii T, Ota M, Hori H, Sasayama D, Hattori K, Teraishi T, et al. Association between the functional polymorphism (C3435T) of the gene encoding Pglycoprotein (ABCB1) and major depressive disorder in the Japanese population. J Psychiatr Res 2012;46:555-9.
9. Hiemke C, Hä rtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000;85:11-28.
10. Ieiri I. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP ABCG2). Drug Metab Pharmacokinet 2012;27:85-105.
11. Kaya P, Gündü z U, Arpaci F, Ural AU, Guran S. Identification of polymorphisms on the MDR1 gene among Turkish population and their effects on multidrug resistance in acute leukemia patients. Am J Hematol 2005;80:26-34. (Pubitemid 41254264)
12. Kerb R, Aynacioglu AS, Brockmö ller J, Schlagenhaufer R, Bauer S, Szekeres T, et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 2001;1:204-10.
13. Kurzawski M, Pawlik A, Gó rnik W, Droździk M. Frequency of common MDR1 gene variants in a Polish population. Pharmacol Rep 2006;58:35-40.
14. Lai Y, Zhang J, Wang YX, Wang XD, Li JL, Wang YH, et al. CYP3A53 and MDR-1 C3435T single nucleotide polymorphisms in six Chinese ethnic groups. Pharmazie 2011;66:136-40.
15. Licinio J, Wong ML. Pharmacogenomics of antidepressant treatment effects. Dialogues Clin Neurosci 2011;13:63-71.
16. Lin KM, Chiu YF, Tsai IJ, Chen CH, Shen WW, Liu SC, et al. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet Genomics 2011;21:163-70.
17. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
18. Milojkovic M, Stojnev S, Jovanovic I, Ljubisavljevic S, Stefanovic V, Sunder-Plassman R. Frequency of the C1236T G2677T/A and C3435T MDR1 gene polymorphisms in the Serbian population. Pharmacol Rep 2011;63:808-14.
19. Nikisch G, Eap CB, Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res 2008;58:344-7.
20. O'Brien FE, Dinan TG, Griffin BT, Cryan JF. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol 2012;165:289-312.
21. Pariante CM. Glucocorticoid receptor function in vitro in patients with major depression. Stress 2004;7:209-19. (Pubitemid 40591421)
22. Peters EJ, Slager SL, Kraft JB, Jenkins GD, Reinalda MS, McGrath PJ, et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR D sample. PLoS One 2008;3:1872.
23. Qian W, Homma M, Itagaki F, Tachikawa H, Kawanishi Y, Mizukami K, et al. MDR1 gene polymorphism in Japanese patients with schizophrenia and mood disorders including depression. Biol Pharm Bull 2006;29:2446-50. (Pubitemid 44885867)
24. Rideg O, Háber A, Botz L, Szü cs F, Vá rnai R, Miseta A, et al. Pilot study for the characterization of pharmacogenetically relevant CYP2D6, CYP2C19 and ABCB1 gene polymorphisms in the Hungarian population. Cell Biochem Funct 2011;29:562-8.
25. Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2002;2:191-6. (Pubitemid 34982226)
26. Rustemoglu A, Gumus-Akay G, Yigit S, Tasliyurt T. Analysis of common MDR1 (ABCB1) gene C1236T and C3435T polymorphisms in Turkish patients with familial Mediterranean fever. Genet Mol Res 2011;10:3411-20.
27. Sakaeda T. MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab Pharmacokinet 2005;20:391-414.
28. Trivedi MH. Major depressive disorder: remission of associated symptoms. J Clin Psychiatry 2006;67:27-32. (Pubitemid 44078110)
29. Turgut S, Turgut G, Atalay EO. Genotype and allele frequency of human multidrug resistance (MDR1) gene C3435T polymorphism in Denizli province of Turkey. Mol Biol Rep 2006;33:295-300. (Pubitemid 44760400)
30. Uhr M, Grauer MT. abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res 2003;37:179-85. (Pubitemid 36313270)
31. Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 2003;54:840-6. (Pubitemid 37205136)
32. Uhr M, Holsboer F, Mü ller MB. Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J Neuroendocrinol 2002;14:753-9.
33. Uhr M, Steckler T, Yassouridis A, Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 2000;22:380-7. (Pubitemid 30105766)
34. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008;57:203-9.
35. Wang D, Sadée W. Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). AAPS J 2006;8:515-20.
36. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003;305:197-204. (Pubitemid 36373851)
37. Wille SM, Cooreman SG, Neels HM, Lambert WE. Relevant issues in the monitoring and the toxicology of antidepressants. Crit Rev Clin Lab Sci 2008;45:25-89. (Pubitemid 351299653)